Navigation Links
Wide disparities in access to latest rheumatoid arthritis drugs across Europe
Date:3/6/2013

This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers.

DMARDs are extremely effective for the treatment of rheumatoid arthritis, and the European League Against Rheumatism (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt progress of the disease. But they are expensive.

The authors therefore surveyed key experts in 49 countries during 2011 about the availability, affordability and acceptability of both synthetic DMARDs, such as methotrexate and leflunomide, and biological DMARDs, such as infliximab and etanercept.

In all, 46 countries took part in the survey, which included those in Eastern Europe, Scandinavia, and Western Europe, as well as Turkey and Uzbekistan.

The responses revealed wide disparities in access to DMARDs. Six countries did not reimburse use of any of the five synthetic DMARDs included in the survey, and 10 countries did not pay for any biological DMARDs.

The cost of one year's treatment with a synthetic DMARD did not exceed any country's per capita GDP). But the cost of one year's treatment with a biological DMARD was higher than the per capita GDP of 26 countries, by as much as 11 times, the findings indicated.

That means that almost 40% of the population of Europe - equivalent to 320 million people - would have severely restricted access to biological DMARDs, say the authors.

Access was especially poor in countries in Central and Eastern Europe and those least well off, economically and socially, the findings showed.

The number of days a person on an average income would need to work to pay fhe full drug price of 30 days' treatment with a biological DMARD ranged from 12 days in Luxembourg to 190 in Romania.

Although it's not possible to draw definitive conclusions on the impact on health of restricted access, higher drugs prices were associated with increased disease activity and poorer physical functioning.

"Assuming needs for treatment with DMARDs are similar across countries, differences in access to medical treatment are unfair and raise alarming issues of inequity," write the authors.

Wealthy Western countries continually debate the budgetary impact of expensive drugs, but unaffordability in low income countries is rarely discussed, they note.

The cheap cost of labour means that these expensive drugs are rarely going to be considered a return on investment, in terms of improved productivity, they add, and drug pricing in Europe should be revised, say the authors.


'/>"/>

Contact: Emma Dickinson
edickinson@bmjgroup.com
44-020-738-36529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Praeclarus Press Launches the One Every 21 Seconds Campaign to Increase Awareness on the Role of Breastfeeding in Reducing Racial/Ethnic Disparities in Infant Mortality
2. Hospital Type Linked to Racial Disparities in Kids With Appendicitis Complication
3. Study reports racial disparities in pediatric appendicitis treatment tied to hospital type
4. Racial Disparities Still Seen in Use of Breast Cancer Treatments
5. Are there racial disparities in osteoporosis screening and treatment?
6. Policy considerations pose options for leaders to reduce costly disparities in diabetes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Orange County partnership to target cancer health disparities
9. Ethnic disparities in breast cancer survival remain despite socioeconomic similarities
10. AACR, Komen for the Cure honor researcher with lecture on science of cancer health disparities
11. Vanderbilt-led study reveals racial disparities in prostate cancer care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of ... Under the care of Maximized Living doctors at the London Olympics in 2012, ... Living is sending the largest contingent of elite chiropractors to Rio to support and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology: